Ouranos Konstantinos, Panteli Manolis, Petasis Georgios, Papachristou Marianthi, Iosifidou Artemis Maria, Iosifidou Myrto Aikaterini, Anastasiou Aikaterini, Samali Margarita, Stangou Maria, Theodorou Ioannis, Lioulios Georgios, Fylaktou Asimina
Department of Medicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
School of Medicine, Aristotle University of Thessaloniki, 45636 Thessaloniki, Greece.
J Clin Med. 2023 Dec 17;12(24):7733. doi: 10.3390/jcm12247733.
Two semi-quantitative, Luminex-based, single-antigen bead (SAB) assays are available to detect anti-HLA antibodies and evaluate their reactivity with complement binding. Sera from 97 patients with positive panel reactive antibody tests (>5%) were analyzed with two SAB tests, Immucor (IC) and One-Lambda (OL), for anti-HLA antibody detection and the evaluation of their complement-binding capacity. IC detected 1608/8148 (mean fluorescent intensity (MFI) 4195 (1995-11,272)) and 1136/7275 (MFI 6706 (2647-13,184)) positive anti-HLA class I and II specificities, respectively. Accordingly, OL detected 1942/8148 (MFI 6185 (2855-12,099)) and 1247/7275 (MFI 9498 (3630-17,702)) positive anti-HLA class I and II specificities, respectively. For the IC assay, 428/1608 (MFI 13,900 (9540-17,999)) and 409/1136 (MFI 11,832 (7128-16,531)) positive class I and II specificities bound C3d, respectively. Similarly, OL detected 485/1942 (MFI 15,452 (9369-23,095)) and 298/1247 (MFI18,852 (14,415-24,707)) C1q-binding class I and II specificities. OL was more sensitive in detecting class I and II anti-HLA antibodies than IC was, although there was no significant difference in the number of class II specificities per case. MFI was higher for complement vs. non-complement-binding anti-HLA antibodies in both assays. Both methods were equal in detecting complement-binding anti-HLA class I antibodies, whereas the C3d assay was more sensitive in detecting complement-binding anti-HLA class II antibodies.
有两种基于Luminex的半定量单抗原珠（SAB）检测方法可用于检测抗HLA抗体并评估其与补体结合的反应性。对97例群体反应性抗体检测呈阳性（>5%）的患者血清，采用两种SAB检测方法，即Immucor（IC）和One-Lambda（OL），进行抗HLA抗体检测及其补体结合能力评估。IC分别检测到1608/8148（平均荧光强度（MFI）4195（1995 - 11272））和1136/7275（MFI 6706（2647 - 13184））抗HLA I类和II类特异性抗体呈阳性。相应地，OL分别检测到1942/8148（MFI 6185（2855 - 12099））和1247/7275（MFI 9498（3630 - 17702））抗HLA I类和II类特异性抗体呈阳性。对于IC检测，428/1608（MFI 13900（9540 - 17999））和409/1136（MFI 11832（7128 - 16531））I类和II类特异性阳性抗体分别结合C3d。同样，OL检测到485/1942（MFI 15452（9369 - 23095））和298/1247（MFI18852（14415 - 24707））I类和II类特异性抗体结合C1q。OL在检测I类和II类抗HLA抗体方面比IC更敏感，尽管每例中II类特异性抗体的数量没有显著差异。在两种检测方法中，与非补体结合的抗HLA抗体相比，补体结合的抗HLA抗体的MFI更高。两种方法在检测补体结合的抗HLA I类抗体方面相当，而C3d检测在检测补体结合的抗HLA II类抗体方面更敏感。
